Is pazopanib/pazopanib a tablet?

Pazopanib/ Pazopanib is an oral medicine that is usually available in tablet form. As a multi-target tyrosine kinase inhibitor, pazopanib is widely used to treat a variety of malignant tumors, such as renal cell carcinoma, soft tissue sarcoma, etc. The drug exerts its anti-tumor effect by inhibiting tumor angiogenesis and growth, thereby blocking the tumor's blood supply, leading to tumor cell apoptosis and growth inhibition.

Pazopanib exists in the form of hydrochloride, and its chemical name is5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide monohydrochloride. Pazopanib hydrochloride is a white to slightly yellow solid and is an oral tablet . Each 200mg pazopanib tablet contains200mgof pazopanib, which is equivalent to 216.7mgof pazopanib hydrochloride.

The pharmacodynamic mechanism of pazopanib mainly includes the inhibition of multiple intracellular receptor tyrosine kinases, the most important of which are the inhibition of vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) and plasminogen kinase receptor (FGFR). These receptors play key roles in tumor angiogenesis and cell proliferation, so inhibition by pazopanib may help curb tumor progression.

As the importance of molecular targeted drugs in clinical applications continues to highlight, pazopanib has been widely studied and used as an effective anti-tumor drug. However, pazopanib also has certain adverse reactions and drug interactions, including but not limited to hypertension, diarrhea, proteinuria, and abnormal liver function. Therefore, patients' physiological indicators should be closely monitored when using pazopanib, and the medication regimen should be adjusted in a timely manner to reduce the occurrence of adverse reactions.